Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Marker Therapeutics (MRKR) over the last 10 years, with Q3 2025 value amounting to -$2.0 million.

  • Marker Therapeutics' Income towards Parent Company rose 1341.01% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.4 million, marking a year-over-year decrease of 10650.12%. This contributed to the annual value of -$10.7 million for FY2024, which is 28473.42% down from last year.
  • Latest data reveals that Marker Therapeutics reported Income towards Parent Company of -$2.0 million as of Q3 2025, which was up 1341.01% from -$4.1 million recorded in Q2 2025.
  • In the past 5 years, Marker Therapeutics' Income towards Parent Company ranged from a high of $6.6 million in Q2 2023 and a low of -$9.8 million during Q1 2022
  • Moreover, its 4-year median value for Income towards Parent Company was -$2.3 million (2024), whereas its average is -$2.2 million.
  • In the last 5 years, Marker Therapeutics' Income towards Parent Company skyrocketed by 26489.77% in 2023 and then crashed by 591800.31% in 2024.
  • Marker Therapeutics' Income towards Parent Company (Quarter) stood at -$813062.0 in 2022, then skyrocketed by 92.26% to -$62939.0 in 2023, then tumbled by 5918.0% to -$3.8 million in 2024, then skyrocketed by 47.23% to -$2.0 million in 2025.
  • Its Income towards Parent Company stands at -$2.0 million for Q3 2025, versus -$4.1 million for Q2 2025 and -$4.4 million for Q1 2025.